This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (127)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Schizophrenia  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

David C. Henderson, MD; Enrico Cagliero, MD; Paul M. Copeland, MD; Christina P. Borba, BS, MPH; Eden Evins, MD; Doug Hayden, MA; Mary T. Weber, PhD, APRN, BC, PMHNP; Ellen J. Anderson, MS, RD, LDN; David B. Allison, PhD; Tara B. Daley, BS, MPH; David Schoenfeld, PhD; Donald C. Goff, MD

Arch Gen Psychiatry. 2005;62:19-28.

Background  While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.

Objective  To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.

Design  A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.

Setting  Subjects were recruited from an urban community mental health clinic and were studied at a general clinical research center.

Patients  Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test. Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.

Main Outcome Measures  Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.

Results  The mean ± SD duration of treatment with the identified atypical antipsychotic agent was 68.3 ± 28.9 months (clozapine), 29.5 ± 17.5 months (olanzapine), and 40.9 ± 33.7 (risperidone). Fasting serum insulin concentrations differed among groups (F₃₃ = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t₃₃ = 2.32; P = .03) and olanzapine and risperidone (t₃₃ = 2.15; P = .04). There was a significant difference in insulin sensitivity index among groups (F₃₃ = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t₃₃ = –4.29; P<.001; olanzapine vs risperidone, t₃₃ = –3.62; P = .001 [P<.001]). The homeostasis model assessment of insulin resistance also differed significantly among groups (F₃₃ = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t₃₃ = 2.94; P = .006; olanzapine vs risperidone, t₃₃ = 2.42; P = .02). There was a significant difference among groups in glucose effectiveness (F₃₀ = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t₃₀ = –2.59; P = .02) and olanzapine and risperidone (t₃₀ = –2.34, P = .03).

Conclusions  Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects. Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.

Author Affiliations: Schizophrenia Program (Drs Henderson, Evins, and Goff and Mss Borba and Daley), Diabetes Research Center (Dr Cagliero), MGH Weight Center and Endocrine Unit (Dr Copeland), Mallinckrodt General Clinical Research Center (Drs Cagliero and Schoenfeld and Mr Hayden and Ms Anderson), Biostatistics Center (Dr Schoenfeld and Mr Hayden), Bionutrition Research (Ms Anderson), Massachusetts General Hospital, Boston; University of Texas at Arlington School of Nursing, Arlington (Dr Weber); Departments of Biostatistics and Nutrition Sciences, University of Alabama at Birmingham, Birmingham (Dr Allison); Harvard Medical School, Boston (Drs Henderson, Cagliero, Copeland, Evins, Schoenfeld, and Goff).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Correll et al.
JAMA 2009;302:1765-1773.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of Noncardiovascular Drugs
Raj et al.
Circulation 2009;120:1123-1132.
FULL TEXT  

Manic/Hypomanic Symptom Burden and Cardiovascular Mortality in Bipolar Disorder
Fiedorowicz et al.
Psychosom. Med. 2009;71:598-606.
ABSTRACT | FULL TEXT  

Health Care for Patients with Serious Mental Illness: Family Medicine's Role
Morden et al.
J Am Board Fam Med 2009;22:187-195.
ABSTRACT | FULL TEXT  

Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem
Dickinson and Harvey
Schizophr Bull 2009;35:403-414.
ABSTRACT | FULL TEXT  

Chapter 23 Therapeutic issues
Semple and Smyth
Oxford Handbook of Psychiatry 2009;2:med-9780199239467-chapter-med-9780199239467-chapter.
FULL TEXT  

Pilot Study of a Cognitive Behavioral Group Intervention to Prevent Further Weight Gain in Hispanic Individuals With Schizophrenia
Weber et al.
J Am Psychiatr Nurses Assoc 2008;13:353-359.
ABSTRACT  

Incidence of Schizophrenia in a Nationwide Cohort of Patients With Type 1 Diabetes Mellitus
Juvonen et al.
Arch Gen Psychiatry 2007;64:894-899.
ABSTRACT | FULL TEXT  

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett et al.
J Psychopharmacol 2007;21:357-373.
ABSTRACT  

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents
Klein et al.
Am. J. Psychiatry 2006;163:2072-2079.
ABSTRACT | FULL TEXT  

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Focus 2006;4:539.
FULL TEXT  

Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup et al.
Am. J. Psychiatry 2006;163:611-622.
ABSTRACT | FULL TEXT  

Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Cohen et al.
Diabetes Care 2006;29:786-791.
ABSTRACT | FULL TEXT  

Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Sikand et al.
JAMA 2006;295:495-495.
FULL TEXT  

The Metabolic Syndrome Is Associated with Reduced Central Serotonergic Responsivity in Healthy Community Volunteers
Muldoon et al.
J. Clin. Endocrinol. Metab. 2006;91:718-721.
ABSTRACT | FULL TEXT  

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
Hosojima et al.
J Psychopharmacol 2006;20:75-79.
ABSTRACT  

An overview of the central control of weight regulation and the effect of antipsychotic medication
Tighe and Dinan
J Psychopharmacol 2005;19:36-46.
ABSTRACT  

Diabetes and schizophrenia 2005: are we any closer to understanding the link?
Holt et al.
J Psychopharmacol 2005;19:56-65.
ABSTRACT  

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman et al.
NEJM 2005;353:1209-1223.
ABSTRACT | FULL TEXT  

Antipsychotics May Impede Glucose Metabolism
Rosack
Psychiatr. News 2005;40:32-47.
FULL TEXT